Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of TherapyWATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed with cemsidomide, an oral IKZF1/3 degrader, in a Phase 1b trial evaluating cemsidomide and dexamethasone in combination with elranatamab (ELREXFIO®), an FDA-approved B-cell m ...

Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing medicines for areas of high unmet need [2] - The company currently has two programs in the clinic, with the most advanced being Cemsidomide, an IKZF1/3 degrader targeting multiple myeloma [2] Clinical Development - C4 Therapeutics completed a Phase I study for Cemsidomide last year and has initiated a Phase II study called MOMENTUM, which began dosing patients last month [2] - The company plans to start a Phase Ib study in Q2 in combination with elranatamab, a BiTE from Pfizer, indicating a differentiated registrational path for its development [3]

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing medicines for areas of high unmet need, particularly in oncology and inflammation [3][5] Key Programs - **Cemsidomide**: - An IKZF1/3 degrader targeting multiple myeloma, currently in a Phase 2 study called MOMENTUM, which started dosing patients last month [3][4] - Expected to start a Phase 1B study in combination with elranatamab (a BiTE from Pfizer) in Q2 [4] - Data from the first-in-human study showed a 53% response rate in heavily pre-treated patients, indicating a foundational role for targeting IKZF1/3 [12][13] - Positioned as a potential best-in-class drug due to optimized catalytic activity, selectivity, and pharmacokinetics [10][11] - **CFT8919**: - An EGFR L858R degrader for non-small cell lung cancer, currently in a Phase 1 study in China, with data expected this month [4][88] - Aims to improve outcomes for patients with the L858R driver mutation [89] Financial Position - C4 Therapeutics reported a strong balance sheet with nearly $300 million at the end of the year, providing runway through the end of 2028 [6] Upcoming Milestones - Key milestones include: - Early data look from the MOMENTUM study in the second half of 2027 [6] - Potential Phase 3 study with the BiTE combination [6] Clinical Trial Insights - The MOMENTUM trial will be conducted in the U.S. and Western Europe, with eligibility criteria focusing on patients with fourth-line plus therapy [18] - The trial aims for regulatory intent, with independent safety data monitoring to ensure data integrity [25][51] - Anticipated response rate for the trial is 40% or greater, with a duration of response expected to be at least six months [36][40] Competitive Landscape - Cemsidomide is positioned to differentiate itself from other therapies, particularly in post-BCMA treatment settings, where it has shown significant activity [49][50] - The drug's unique pharmacokinetics allow for a 14-day on, 14-day off dosing schedule, which is pharmacologically optimized [79][84] Collaboration and Discovery Efforts - C4 Therapeutics is collaborating with Roche, Merck KGaA, and Biogen to develop degraders against targets of interest [5] - The company is also exploring internal programs focused on inflammation, neuroinflammation, and neurodegeneration [5] Conclusion - C4 Therapeutics is positioned for significant growth with its innovative drug candidates and strong financial backing, focusing on addressing unmet medical needs in oncology and beyond [6][88]

Core Insights - The article emphasizes the importance of combining scientific expertise with financial analysis in the biotechnology sector to identify promising investment opportunities [1]. Group 1: Industry Focus - The biotechnology sector is characterized by innovation through unique mechanisms of action, first-in-class therapies, and platform technologies that can reshape treatment paradigms [1]. - The analysis will cover companies at various stages of development, from early clinical pipelines to commercial-stage biotechs, highlighting the significance of evaluating the science behind drug candidates [1]. Group 2: Analytical Approach - The approach includes assessing the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]. - The goal is to provide insights that help investors understand both the opportunities and risks inherent in the biotech sector, where breakthrough science can lead to significant returns [1].

Group 1 - C4 Therapeutics Inc. (NASDAQ:CCCC) is recognized as one of the 11 most popular AI penny stocks to buy, with a price target increase from $20 to $30 by Brookline, reflecting growing confidence in the company's developments [1] - The Phase 2 MOMENTUM trial for cemsidomide, which has shown a differentiated safety and tolerability profile, is expected to support its use in second-line and later patient populations [2] - The first patient has been dosed in the Phase 2 MOMENTUM trial, which evaluates cemsidomide in combination with dexamethasone for relapsed or refractory multiple myeloma, building on previous positive results from the Phase 1 study [3][4] Group 2 - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel targeted protein degradation therapies aimed at treating cancer and other serious diseases [5] - The company has established strategic partnerships with notable firms such as Merck KGaA, Biogen, and Betta Pharmaceuticals, enhancing its development capabilities [5]

Core Viewpoint - C4 Therapeutics, Inc. (CCCC) is identified as a promising momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy) [2][3][11] Price Performance - CCCC shares have increased by 25% over the past week, significantly outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 1.38% during the same period [5] - Over the last month, CCCC's price change is 77.19%, compared to the industry's 0.91% [5] - In the last quarter, CCCC shares rose by 19.29%, and over the past year, they gained 28.39%, while the S&P 500 experienced a decline of -0.32% in the last quarter and a gain of 18.16% over the past year [6] Trading Volume - The average 20-day trading volume for CCCC is 2,449,020 shares, indicating a bullish sign as the stock is rising with above-average volume [7] Earnings Outlook - In the past two months, two earnings estimates for CCCC have been revised upward, while none have been revised downward, leading to an increase in the consensus estimate from -$1.22 to -$1.02 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions during the same period [9]

Core Insights - The company is focused on the development of transcript-related projects, indicating a commitment to enhancing its offerings in this area [1] Group 1 - The company publishes thousands of quarterly earnings calls each quarter, showcasing its extensive coverage and growth in the transcript publishing sector [1]

Company Performance - BrightSpring Health Services, Inc. (BTSG) has returned 12% year-to-date, outperforming the average return of 1% for Medical companies [4] - The Zacks Consensus Estimate for BTSG's full-year earnings has increased by 8.2% over the past quarter, indicating improving analyst sentiment [4] - BTSG currently holds a Zacks Rank of 1 (Strong Buy), suggesting strong potential for future performance [3] Industry Comparison - BrightSpring Health Services, Inc. is part of the Medical Services industry, which has seen a decline of about 2.9% year-to-date, indicating that BTSG is performing better than its industry peers [6] - In contrast, C4 Therapeutics, Inc. (CCCC), another outperforming stock in the Medical sector, has increased by 61.8% year-to-date, with a Zacks Rank of 2 (Buy) [5][7] - The Medical group consists of 926 companies, with BrightSpring Health Services ranked 8 in the Zacks Sector Rank [2]

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing a sustainable pipeline of medicines, particularly in oncology [2][3] - The company has a validated clinical oncology portfolio, including cemsidomide, an IKZF1/3 degrader [2] Key Developments and Milestones - C4 Therapeutics completed a financing round in October 2025, providing runway through the end of 2028 [3] - The MOMENTUM Phase II study has started enrollment, with patients already dosed [4] - A Phase 1b study in combination with elranatamab is expected to start next quarter [4] - The company anticipates having registrational data from the MOMENTUM study by 2028, along with the first NDA submission [5] Cemsidomide Insights - Cemsidomide is positioned as a best-in-class IKZF1/3 degrader, with a competitive efficacy profile compared to other drugs in the same class [7][8] - The drug has shown a response rate of 36% across all doses in Phase I, with a peak response rate of 53% at the highest dose [33] - Cemsidomide has a favorable safety profile, with only 6% of patients requiring dose reductions due to treatment-related adverse events [13] Market Opportunity - The myeloma market is large and growing, with an estimated peak revenue opportunity of $2.5 billion to $4 billion by 2030 [18] - There are approximately 22,000 patients in the fourth-line setting in the U.S. and EU, with expectations for growth as newer agents move into earlier lines of treatment [16] Combination Therapy Potential - The combination of cemsidomide with elranatamab (a BCMA BiTE) is expected to enhance efficacy, potentially bringing response rates on par with CAR T therapies [17][54] - The company is also exploring combinations with other agents like carfilzomib and CD38 [60] Discovery Strategy - C4 Therapeutics is focusing on inflammation, neuroinflammation, and neurodegeneration, with plans to develop first-in-class drugs against undruggable targets [19][20] - The company has identified three validated pathways and five novel targets for future development [20][21] Regulatory Considerations - The company is preparing for Accelerated Approval by ensuring high-quality data and independent evaluation of efficacy endpoints [44][45] - The recent FDA draft guidance on MRD negativity will be integrated into the Phase III trial design [48][49] Underappreciated Aspects - Cemsidomide is viewed as a foundational asset in myeloma care, with a best-in-class potential that is not fully appreciated by investors [65][66] - The unique mechanism of action and safety profile of cemsidomide may provide significant advantages in a competitive landscape [66][67]

Drug Development and Trials - Cemsidomide, an orally bioavailable degrader targeting IKZF1/3, has shown compelling anti-myeloma activity in Phase 1 trials, with a differentiated safety profile[24][32]. - The Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone is set to enroll approximately 100 patients, with an expected initiation in Q1 2026[33]. - The Phase 1b trial of cemsidomide in combination with elranatamab aims to assess safety and tolerability, with a focus on enhancing response depth while maintaining a manageable safety profile[35]. - CFT8919, an allosteric degrader of EGFR L858R, is being developed in collaboration with Betta Pharma for the Greater China market, with the first patient dosed in November 2024[43]. - CFT8919 is designed to overcome resistance to standard EGFR inhibitors, with the potential for deeper and more durable responses in NSCLC patients[39][42]. - The company is focused on the discovery and development of protein degradation therapies using its TORPEDO platform, facing competition from various biotechnology and pharmaceutical companies[84]. - The company is in the early stages of product development and may take several years before any product candidates are ready for regulatory approval and commercialization[201]. - The company is focused on leveraging its TORPEDO platform to identify and advance additional product candidates into preclinical and clinical development[204]. Market Need and Patient Population - Approximately 65,370 new cases of multiple myeloma were reported in the US, UK, Germany, France, Spain, and Italy in 2024, indicating a significant unmet need in this patient population[37]. - The annual prevalence of multiple myeloma in the fourth-line setting was approximately 42,000 patients across the US, UK, Germany, Italy, France, and Spain in 2024[33]. - Approximately 419,380 patients were diagnosed with non-small cell lung cancer (NSCLC) in 2024, with 10-15% having mutant EGFR, highlighting the market potential for CFT8919[44]. - The EGFR L858R mutation accounts for approximately 40% of EGFR diagnoses in the US and China, with a median progression-free survival (PFS) of 14.4 months when treated with osimertinib, compared to 21.4 months for exon19 deletion patients[45]. Collaborations and Partnerships - The collaboration with Merck KGaA and Roche aims to expand the development of novel degraders across multiple therapeutic areas, enhancing the utility of the TORPEDO platform[26][31]. - The collaboration with Betta Pharma involves the development of CFT8919, a BiDAC degrader targeting the EGFR L858R mutation, specifically for the Greater China market[66]. - The collaboration with Betta Pharma is managed by a joint steering committee composed of representatives from both companies[69]. - The Pfizer Agreement allows for the supply of elranatamab for a Phase 1b trial at no cost, with the company sponsoring and conducting the trial[63]. - Betta Pharma made an upfront cash payment of $10.0 million and the company is eligible to receive up to $357.0 million in milestone payments for CFT8919 in Greater China[67]. - The royalty rates from Betta Pharma to the company range from low to mid double-digit percentages on net sales of CFT8919 in Greater China[67]. - The collaboration with Merck KGaA includes an upfront cash payment of $16.0 million and potential milestone payments totaling approximately $740 million, plus tiered royalties on net sales[64]. - Roche is obligated to pay an exercise fee of $8.0 million for each of the two remaining targets if it exercises its option rights[75]. - The company is eligible to receive milestone payments up to $273.0 million from Roche upon achieving certain research, development, and commercial milestones for corresponding products[75]. - Biogen paid an upfront payment of $45.0 million upon execution of the Biogen Agreement for candidate development activities[81]. - Biogen is required to pay the company development and commercialization milestone payments totaling up to $35.0 million for each target[81]. - The company received a total of $16.0 million from Biogen in 2024 for two development candidates that commenced IND-enabling studies[81]. Financial Overview - The net loss for the company was $105.0 million for the year ended December 31, 2025, compared to a net loss of $105.3 million for 2024, with an accumulated deficit of $738.7 million as of December 31, 2025[201]. - The company has not generated any revenue from product sales to date and has primarily financed operations through equity sales and collaborations[201]. - The company expects to incur significant expenses and increasing operating losses for at least the next several years, with anticipated substantial increases in expenses related to public company operations[202]. - The company anticipates that its current cash resources will not be sufficient to fund product candidates through regulatory approval, necessitating additional capital[210]. - The company raised net proceeds of approximately $117.0 million from the 2025 Offering after deducting underwriting discounts and expenses[208]. - The company expects to incur significant commercialization expenses if any product candidates are approved, which may impact profitability[211]. - Future capital requirements will depend on the costs and results of ongoing and planned Phase 1/2 clinical trials and other development programs[209]. - The company may face dilution of stockholder ownership if additional capital is raised through equity offerings[215]. - The company’s financial condition and operating results are expected to fluctuate significantly from quarter to quarter and year to year[214]. Regulatory Environment - The FDA regulates the clinical development and marketing of pharmaceutical products, requiring substantial time and financial resources for compliance[111]. - The process for obtaining FDA approval involves significant time, effort, and financial resources, with potential sanctions for non-compliance[113]. - The FDA's IND application must include preclinical test results, manufacturing information, and analytical data before clinical trials can commence[115]. - Clinical trials are conducted in three phases: Phase 1 focuses on safety and dosage, Phase 2 evaluates preliminary efficacy and safety, and Phase 3 provides statistically significant evidence of efficacy[126]. - The FDA has implemented Project Optimus to reform dose selection in oncology drug development, emphasizing safety and tolerability alongside efficacy[121]. - The FDA's accelerated approval pathway allows drugs to be approved based on surrogate endpoints that predict clinical benefit, subject to post-marketing compliance requirements[133]. - Priority review designation by the FDA reduces the review goal to six months for drugs that significantly improve safety or effectiveness[135]. - The submission of an NDA requires a substantial user fee, which must be paid at the time of the first application submission[137]. - The Pediatric Research Equity Act mandates that NDAs include data on safety and efficacy for relevant pediatric subpopulations[138]. - The FDA may refer applications for drugs with unapproved active ingredients to an advisory committee for evaluation and recommendations[139]. - Companies must submit progress reports detailing clinical trial results at least annually to the FDA, with more frequent updates for serious adverse events[125]. - The manufacturing of investigational drugs must comply with current Good Manufacturing Practices (cGMP) to ensure quality and safety[128]. - The FDA's review goal for a standard NDA for a new molecular entity (NME) is 10 months from the 60-day filing date, while priority review applications aim for 6 months[141]. - The FDA may grant 5 years of exclusivity for new chemical entities (NCEs) following approval, preventing the acceptance of ANDA applications for the same active moiety during this period[153]. - Orphan drug designation can provide 7 years of exclusivity for drugs treating rare diseases, with specific conditions for maintaining this exclusivity[155]. - The FDA requires ongoing compliance with cGMP and may impose additional post-marketing requirements, including Phase 4 studies, to monitor safety and efficacy[146]. - The EU's Clinical Trials Regulation aims to streamline the approval process for clinical trials, establishing strict deadlines for assessment[159]. - The EMA's PRIME scheme supports the development of medicines targeting unmet medical needs, potentially expediting the approval process[161]. - In the EU, centralized marketing authorizations are mandatory for certain products, including those produced by biotechnological processes and orphan medicinal products[162]. - The FDA may issue a Complete Response Letter (CRL) if an NDA is not ready for approval, outlining specific conditions for resubmission[143]. - The FDA enforces strict regulations on drug marketing, prohibiting claims inconsistent with approved labeling, which can lead to significant liabilities[150]. - Failure to comply with FDA requirements can result in severe sanctions, including withdrawal of approval and fines[152]. - The company is focused on obtaining pediatric-use marketing authorization (PUMA) for its products, which allows for exclusive development for children[164]. - The European Union grants orphan designation for products intended for life-threatening conditions affecting no more than five in 10,000 persons, providing financial incentives and 10 years of market exclusivity[165][166]. - The China National Medical Products Administration (NMPA) has implemented an implied approval system for clinical trials, allowing trials to proceed if no objections are raised within 60 business days[168]. - The NMPA finalized guidelines to encourage the development of innovative oncology drugs, aiming to reduce the prevalence of "me-too" drugs with minimal clinical value[169]. - Clinical trials in China must be registered within one month of approval, with penalties for non-compliance leading to automatic expiration of trial approval after three years[170]. - The company must navigate complex healthcare laws and regulations, including the federal Anti-Kickback Statute and the False Claims Act, which impose significant penalties for violations[172][175]. Competitive Landscape - The company faces significant competition from larger firms with greater financial resources and expertise in R&D, manufacturing, and regulatory approvals[89]. - The company expects its product candidates, if approved, to be priced at a significant premium over competitive generic products[90]. - The company relies on third-party contract manufacturing organizations (CMOs) for drug candidate supplies, which may pose risks related to availability and quality[91]. - The company has not yet established its own commercial organization, planning to build a specialized sales and marketing team for commercialization in the U.S.[92]. - The company relies on trade secrets and technical know-how to maintain its competitive advantage[109]. - The scientific evidence supporting the feasibility of developing TORPEDO platform-derived treatments is preliminary and limited[219]. - The development of product candidates based on the TORPEDO platform is unproven, making it difficult to predict development timelines and costs[218]. Employee and Workplace Culture - As of December 31, 2025, the company employed 104 full-time employees, including 40 with M.D. and/or Ph.D. degrees, with 69 engaged in research and development activities[192]. - The company is committed to creating an inclusive workplace and has implemented programs to support employee well-being and development[194]. Legislative and Economic Factors - Coverage and reimbursement for drug products in the U.S. vary significantly among third-party payors, impacting sales and financial performance[176][178]. - The company may need to conduct pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of its products to secure reimbursement[177]. - Legislative changes, such as the Affordable Care Act (ACA), continue to influence coverage and payment structures for healthcare products in the U.S.[180]. - The containment of healthcare costs is a priority for governments, which may implement price controls and restrictions that could limit revenue from approved products[179]. - The company faces risks related to potential legislative changes affecting drug pricing and reimbursement, which could adversely impact future revenues[200]. - The company is subject to ongoing litigation regarding the constitutionality of the Inflation Reduction Act's Medicare drug price negotiation program, which may affect its business[184]. - The company anticipates that the implementation of proposed MFN pricing models could significantly impact its pricing and revenue structure starting in 2026[188].